Boviseal Dry Cow Intramammary Infusion

Χώρα: Ιρλανδία

Γλώσσα: Αγγλικά

Πηγή: HPRA (Health Products Regulatory Authority)

Δραστική ουσία:

Bismuth subnitrate

Διαθέσιμο από:

Cross Vetpharm Group Limited

Φαρμακολογική κατηγορία (ATC):

QJ51X

INN (Διεθνής Όνομα):

Bismuth subnitrate

Δοσολογία:

2.6 g/syringe

Φαρμακοτεχνική μορφή:

Intramammary Infusion

Τρόπος διάθεσης:

LM: Licensed Merchant as defined in relevant national legislation

Θεραπευτική ομάδα:

Cattle

Θεραπευτική περιοχή:

OTHER ANTIBACTERIALS FOR INTRAMAMMARY USE

Θεραπευτικές ενδείξεις:

Miscellaneous

Καθεστώς αδειοδότησης:

Authorised

Ημερομηνία της άδειας:

2003-06-30

Αρχείο Π.Χ.Π.

Health Products Regulatory Authority
08 January 2018
CRN000WLS
Page 1 of 5
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Boviseal Dry Cow Intramammary Infusion
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance
Bismuth subnitrate 2.6g per 4g syringe
For a full list of excipients, see Section 6.1
3 PHARMACEUTICAL FORM
Intramammary infusion, dry cow.Grey to white coloured cream.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dairy cows at the end of lactation.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Boviseal is indicated for the prevention of new intramammary
infections throughout
the dry period. This results in a reduction in the incidence of
subclinical mastitis in
cows at calving, and of clinical mastitis in the dry period and the
subsequent
lactation (for at least 60 days after calving).
It is recommended that Boviseal be used as part of a herd approach to
dry cow
management and mastitis control. Cows considered likely to be free of
subclinical
mastitis should be given Boviseal at drying off according to the
criteria below. Other
animals should be managed in accordance with an approved mastitis
control plan or
specific veterinary advice.
For practical purposes, selection criteria may be based on the
mastitis and cell count
history of individual cows, or recognised tests for the detection of
subclinical mastitis
or bacteriological sampling. It is particularly important that, prior
to treatment, an
individual cell count be obtained from any cow with a history of
clinical mastitis
during the previous lactation. As a guide, cows with an average cell
count less than
200,000 cells/ml before drying off may be given Boviseal. A minor
increase (cell count
up to 250,000 cells/ml) during the last 4 weeks before drying off is
normal and may
be ignored. In case of doubt, veterinary advice should be sought.
Health Products Regulatory Authority
08 January 2018
CRN000WLS
Page 2 of 5
4.3 CONTRAINDICATIONS
Do not use in the lactating cow.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Details provided above apply.